Complete financial analysis of Upstream Bio, Inc. (UPB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Upstream Bio, Inc., a leading company in the None industry within the None sector.
You may be interested
- Aditya Birla Fashion and Retail Limited (ABFRL.NS) Income Statement Analysis – Financial Results
- Leslie’s, Inc. (LESL) Income Statement Analysis – Financial Results
- River Hawk Aviation, Inc. (RHWI) Income Statement Analysis – Financial Results
- UOL Group Limited (U14.SI) Income Statement Analysis – Financial Results
- EDP Corporation (7794.T) Income Statement Analysis – Financial Results
Upstream Bio, Inc. (UPB)
Unable to fetch income statement for: UPB
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the closing of its upsized initial public offering...
Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut
Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.
Upstream Bio raises $255 mln in US IPO
Upstream Bio , which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States.
Upstream Bio Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the pricing of its upsized initial public offering...
Source: https://incomestatements.info
Category: Stock Reports